Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
The aim of this study was to evaluate the effect of Cabergoline on insulin sensitivity, inflammatory markers, and carotid intima media thickness in prolactinoma patients. Twenty-one female, newly diagnosed patients with prolactinoma were included in the study. None of the patients were treated previously. Cabergoline was given as treatment, starting with 0.5 mg/day and tapered necessarily. Blood samples were taken for prolactin, highly sensitive C-reactive protein, homocysteine, total cholesterol, low density lipoprotein (LDL) cholesterol, fasting glucose, insulin, and HOMA (homeostasis model assessment of insulin resistance) score was calculated, prior to and 6 months after starting treatment. The body mass index (BMI) was measured and carotid intima media thickness (CIMT) was evaluated for each patient prior to and 6 months after the treatment. The prolactin levels and LDL decreased significantly after cabergoline treatment. Insulin sensitivity improved independently from the decrease in prolactin levels and BMI. The significant decrease in homocysteine and hs-CRP was not related with the decrease in prolactin levels. The significant decrease in CIMT was independent from the decrease in prolactin levels, HOMA score, and BMI. Our data suggest that cabergoline treatment causes an improvement in insulin sensitivity and inflammatory markers and causes a decrease in CIMT independent from the decrease in prolactin, LDL cholesterol, and BMI. We conclude that short term cabergoline…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Bots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Wada, K., Tanaka, K., & Nakashima, K. (2011) · PubMed · Cited by 1,132
Dorshkind, K., & Horseman, N. D. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0397 · Cited by 371
Dorshkind, K. (2000) · Endocrine Reviews · doi:10.1210/er.21.3.292 · Cited by 370
Focus on prolactin as a metabolic hormone
Ben-Jonathan, N., Hugo, E. R., Brandebourg, T. D., & LaPensee, C. R. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.02.005 · Cited by 339
Greenman, Y., Tordjman, K., & Stern, N. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00403.x · Cited by 227
Santos‐Silva, C. M., Barbosa, F. R. P., Lima, G. A. B., Warszawski, L., Fontes, R., Domingues, R. C., & Gadelha, M. R. (2011) · Obesity · doi:10.1038/oby.2010.150 · Cited by 183
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine
Doknic, M., Pekic, S., Zarkovic, M., Medic-Stojanoska, M., Dieguez, C., Casanueva, F., & Popovic, V (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470077 · Cited by 172
Prolactin: A diabetogenic hormone
Landgraf, R., Landgraf-Leurs, M. M. C., Weissmann, A., Hörl, R., von Werder, K., & Scriba, P. C. (1977) · Diabetologia · doi:10.1007/bf00745135 · Cited by 167
Cited by
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL)
Huang, J.-K., & Lee, H.-C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084300 · Cited by 102
Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders
Hazlehurst, J. M., & Tomlinson, J. W. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0296 · Cited by 97
Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
Pala, N. A., Laway, B. A., Misgar, R. A., & Dar, R. A. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0094-4 · Cited by 94
Hypothalamic dopamine signalling regulates brown fat thermogenesis
Folgueira, C., Beiroa, D., Porteiro, B., Duquenne, M., Puighermanal, E., Fondevila, M. F., Barja-Fernández, S., Gallego, R., Hernández-Bautista, R., Castelao, C., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0099-7 · Cited by 85
Metabolic effects of prolactin and the role of dopamine agonists: A review
Kirsch, P. M., Kunadia, J., Shah, S., & Agrawal, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1002320 · Cited by 87
“Inancli (101) 2013 21 30 +/-10 100 14 Cabergoline 0.”
Metadata
- Authors
- Inancli, S. S., Usluogullari, A., Ustu, Y., Caner, S., Tam, A. A., Ersoy, R., & Cakir, B.
- Affiliations
- Ankara Atatürk Eğitim ve Araştırma Hastanesi (TR)
- Venue
- Endocrine
- Published
- 2012-12-12
- Volume
- 44
- Issue
- 1
- Pages
- 193-199
- ISSN
- 0969-711X (ISSN-L)
- 1355-008X
- 1559-0100
- OpenAlex
- W2005558563
- Cited by
- 59
- References
- 38
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 7 · 2023: 6 · 2022: 3 · 2021: 5 · 2019: 6 · 2017: 2 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 6
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Endocrine (publishedVersion)
- PubMed (publishedVersion)
- AYBU AVESIS (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- cabergoline, prolactinoma, insulin sensitivity, insulin resistance, carotid intima-media thickness, endothelial function, inflammation, C-reactive protein, homocysteine, prolactin, LDL cholesterol, body mass index, dopamine agonist therapy
- MeSH terms
- Cabergoline, Adolescent, Adult, Ergolines, Female, Glucose Tolerance Test, Humans, Inflammation, Insulin Resistance, Middle Aged, Pituitary Neoplasms, Prolactinoma, Biomarkers, Antineoplastic Agents, Hormonal, Young Adult, Carotid Intima-Media Thickness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. https://app.cochat.ai/papers/10.1007/s12020-012-9857-y
- The paper
- Inancli, S. S., Usluogullari, A., Ustu, Y., Caner, S., Tam, A. A., Ersoy, R., & Cakir, B. (2013). Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine. https://doi.org/10.1007/s12020-012-9857-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.